Cardiovascular Medical Devices / Cardiac & Vascular Surgery
Strategic Profile
Recent acquisitions and partnerships have empowered the company to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves and aortic stents and stent grafts. The company focuses on aortic stent grafts, On-X mechanical valves, surgical sealants and preserved tissues, investing $31M in R&D while navigating intense competition, complex global regulations and supply-chain risks across North America, Europe, APAC and Latin America.
Cyborg Score Rationale
Artivion operates in a specialized high-value cardiac surgery niche with strong product differentiation through its aortic-focused portfolio. Q1 2025 showed modest YoY growth with $99.0M revenue and updated FY25 guidance of $423-435M. However, recent operational challenges including a November 2024 cybersecurity incident and tissue backlog issues partially offset strong product-specific growth momentum.
Top Insights
Achieved clearing 1/3 of the tissue backlog ahead of schedule with a strong U.S. AMDS launch with 150 active accounts following stabilization after November 2024 cybersecurity incident.
Strong year-over-year product performance includes stent graft revenue up 14-19%, On-X growth of 10-11%, and BioGlue up 7%.
Artivion has over 1,250 employees worldwide with sales representation in over 100 countries.
Faces intense competition from large device makers and other tissue processors, as well as regulatory, quality, and supply-chain risks including dependence on single- and sole-source suppliers.
Named Competitors
Aortic & Vascular Division — Large diversified competitor in aortic/vascular stent grafts and endovascular solutions
Cardiovascular Solutions — Leader in heart valve replacement and structural heart disease treatment
Cardiovascular Division — Diversified player in vascular grafts and cardiac surgical devices
Recent Developments
(Q1 2025) Updated FY25 revenue guidance to $423-435M; cleared tissue backlog ahead of schedule; strong AMDS launch with 150 active accounts
(May 2025) NEXUS TRIOMPHE IDE trial demonstrated significant clinical improvements at AATS Annual Meeting